CVS Health (CVS) confirmed plans Tuesday to split into two publicly traded companies, separating its roughly 9,000-store retail pharmacy chain from its Aetna insurance and Caremark pharmacy-benefit management units, a structural overhaul that analysts say could unlock meaningful valuation upside for shareholders.
The move is significant for long-horizon investors because CVS shares currently trade at 10.8 times 2027 adjusted earnings – well below the 10-year sector average of 15.7 times – suggesting the integrated conglomerate structure has weighed on the stock’s multiple for years. 1
Key Takeaways
- CVS splits into two public companies: retail pharmacy and insurance/PBM.
- Shares trade at a steep discount to the 10-year sector average multiple.
- CEO Joyner says regulatory pressure did not drive the decision.
The Two New Entities: Structure and Assets
One company will retain the CVS Health name, be led by Chief Executive David Joyner, and house Aetna, Caremark, Oak Street Health primary-care clinics, Signify Health home-visit services, and CVS’s specialty-drug business. The second, to be called CVS Pharmacy, will encompass retail drugstores, mail-order pharmacy, and the MinuteClinic chain. 1
The two businesses will maintain certain commercial agreements with each other after separation, Joyner said, preserving some of the operational linkages built since CVS’s $78 billion acquisition of Aetna nearly a decade ago. The split effectively unwinds the core thesis of that deal – that scale across insurance, PBM, and retail could bend America’s healthcare cost curve. 1
Market Reaction & Valuation Context
CVS shares were up just 0.1% in extended trading on Tuesday, a muted response that may reflect investor caution ahead of the company’s quarterly earnings report due Wednesday. 1
The stock has nonetheless rebounded significantly under Joyner, who took over as CEO in October 2024 following the dismissal of Karen Lynch, lifting CVS’s market capitalisation to approximately $117 billion. By comparison, peer Walgreens was taken private by Sycamore Partners last year after a drawn-out sale process that underscored the limited buyer universe for standalone retail pharmacy assets. 1
Detailed Analysis: Why the Break-Up Case Is Compelling
Mizuho analyst Ann Hynes said the valuation gap argues strongly for separation.
“We believe separating the insurance business could unlock meaningful multiple expansion potential for shareholders, who would be expected to retain ownership stakes in both newly formed companies,” Hynes said. 1
Evercore ISI analyst Elizabeth Anderson added a regulatory dimension, noting that “a potential split could also help relieve some regulatory concerns – particularly at the state level – regarding joint ownership of a PBM and retail drug store.” 1 This matters because pharmacy benefit managers are under growing scrutiny from both federal regulators and state legislatures over their role as drug-pricing middlemen; the Federal Trade Commission settled a case with CVS this past summer restricting how Caremark does business with competing pharmacies.
The Trump administration is also drafting rules requiring greater pricing transparency across integrated health businesses, adding further incentive to simplify the corporate structure – even though Joyner explicitly told the Wall Street Journal that regulatory pressure was not the primary driver. 1
Structural Headwinds for the Retail Pharmacy Unit
CVS Pharmacy will inherit a challenging operating environment. Foot traffic has eroded as consumers shift prescriptions to home delivery and migrate general merchandise purchases to Amazon, while in-store product security measures – items locked behind glass – have degraded the shopping experience. 1
Aetna, meanwhile, has pulled back from Affordable Care Act exchanges and trimmed Medicare Advantage benefits in response to surging medical costs that have pressured health insurers industry-wide since the end of the COVID-19 pandemic. Joyner said Aetna’s Medicare business will be strengthened by the Signify and Oak Street assets, both of which are oriented toward Americans aged 65 and older. 1
Management Rationale and Outlook
“We believe based off of where we are and how we’re performing, the businesses are best served by splitting,” Joyner said, according to the Wall Street Journal. “We’re basically taking what I believe is one great company and making it two.” 1
No timeline for the separation was disclosed ahead of Wednesday’s earnings call. Investors will likely scrutinise guidance on how transaction costs, dis-synergies, and the allocation of corporate debt between the two entities could affect near-term cash flows. 1
Conclusion
For long-horizon investors, the central question is whether two focused, independent businesses can each command the sector-average multiple that the integrated CVS has failed to achieve. If Mizuho’s thesis proves correct, existing shareholders – who are expected to receive stakes in both companies – could see meaningful valuation re-rating without any change to the underlying earnings streams. The retail pharmacy unit faces the steeper climb given structural industry pressures, while the insurance-and-PBM entity carries both higher near-term regulatory risk and arguably the stronger earnings-growth profile through Aetna’s Medicare positioning and Caremark’s entrenched PBM contracts. 1
Not investment advice. For informational purposes only.
References
1Sabrina Valle and Siddhi Mahatole (2026-11-03). “CVS will split up its pharmacy and insurance business into two companies, WSJ says”. Reuters / KELO-AM. Retrieved 2026-11-03.
2(2026-11-03). “CVS Health will split into two companies, dividing its retail pharmacies from its insurance and pharmacy-benefit operations”. The Wall Street Journal. Retrieved 2026-11-03.